NCT03801148View on ClinicalTrials.gov

A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules

PHASE1CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

January 10, 2019

Primary Completion Date

February 25, 2019

Study Completion Date

April 9, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

30 mg dexlansoprazole capsules manufactured at TOB

Dexlansoprazole delayed-release capsules.

DRUG

30 mg dexlansoprazole capsules manufactured at TPC

Dexlansoprazole delayed-release capsules.

DRUG

60 mg dexlansoprazole capsules manufactured at TOB

Dexlansoprazole delayed-release capsules.

DRUG

60 mg dexlansoprazole capsules manufactured at TPC

Dexlansoprazole delayed-release capsules.

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT03801148 - A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules | Biotech Hunter | Biotech Hunter